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ABSTRACT
Inborn errors of metabolism (IEMs) are a class of genetic disorders that are rare individually, but collectively they occur in common terms exhibiting 
an average prevalence of 1 in 1000 individuals. One of the most commonly occurring IEMs is the urea cycle disorders (UCDs), which are a group 
of unusual disorders that have an effect on the urea cycle, a sequence of metabolic processes through which nitrogen is transformed into urea and 
expelled from the body by the urine. These diseases are the primary cause of hereditary hyperammonemia, and they can result in developmental 
disabilities, epilepsy, loss of psychomotor control, and death. UCDs are most commonly diagnosed during infancy, although certain infants do not 
exhibit symptoms until they are in their early childhood. IEMs are precisely diagnosed and recorded through tandem mass spectroscopy-based 
newborn screening. Recent advances in IEMs include new therapies based on dietary modification, enzyme replacement therapy, development 
of novel compounds, and diagnosis involving untargeted metabolomics and whole-exome sequencing are also widely being used in new disease 
discovery. Modern improvements in diagnosis and care have increased the prognosis significantly for a lot of children with IEM. It has been suggested 
that expanded access to awareness of IEMs is the most significant change leading to better treatment. The purpose of this review is to provide an 
overview on IEM and present in-depth knowledge about the UCDs including their subtypes.
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INTRODUCTION
Given the existence of conventional biochemical technologies in 
the 20th century, the inborn metabolic errors originally identified 
were usually diseases of intoxication manifesting in the central 
nervous system or different end-organ consequences [1]. Inborn 
errors of metabolism (IEM) are inherited single gene defects caused 
by a malfunction or abnormality in a transporter, an enzyme or its 
cofactor, leading to substrate aggregation or the product deficiency. Sir 
Archibald Garrod described these diseases for the first time in 1908 and 
submitted his study titled “Inborn Errors in Metabolism” to the Royal 
College of Physicians as the Croonian Lectures [2-4]. More than 700 
IEMs were known till date [5]. IEM is rare, but their overall occurrence 
is greater than 1:1000 and is responsible for a considerable portion of 
disability and deaths during childhood [6]. Most of the IEM disorders 
are autosomal recessive type, but X-linked and autosomal dominant 
disorders are also existent. Since neonates with IEMs typically present 
with nonspecific symptoms [7], a high note of suspicion is critical 
for early detection of IEMs. Hence, any previous records of paternal 
affiliation or a formerly infected sibling may indicate the possibility of 
IEMs.
The IEMs can be classified into two categories: Those caused by 
abnormalities in energy sources metabolism such as proteins, 
carbohydrates, or lipids and those caused by disruption in pathways 
occurring within cell organelles such as peroxisome, mitochondria, 
and lysosome. Urea cycle disorders (UCDs), chemical acidemias, and 
amino acidopathies are examples of metabolic disorders affected by 
protein metabolism disorder. Defects of fatty acid b-oxidation and the 
carnitine shuttle are examples of lipid metabolism disorders. Among 
the carbohydrate diseases are galactosemia and glycogen storage 
disorders. The storage disorders of lysosomes are caused by disability 
to digest or recycling of complex large macromolecules and might 
manifest with a variety of symptoms, based on the enzymatic block. 
Of the most significant laboratory outcomes associated with inborn 
metabolic errors, urea cycle defects [8], and certain organic acidemias 
are at the top.
UCDs are a type of inborn error in hepatic metabolism [9] caused by 
the lack of enzymatic activities that control the transfer of nitrogen 
from ammonia to urea. With an average prevalence of at least 1 in 
2500, these conditions often lead to lethal hyperglutaminemia and 
hyperammonemia [10,11]. The manifestations of UCDs vary with 
independent of the age, although they are most probably to appear 
during the late infancy, neonatal stage, and at the time of puberty. 
Early signs are generally nonspecific, so it is crucial to regularly 
screen for hyperammonemia to determine a diagnosis rapidly and 
avoid complications. A disorder known as transient hyperammonemia 
of the newborn is of the differential diagnosis in neonates, while 
in older infants the defects of fatty acid oxidation may be taken into 
consideration [12,13]. The toxic ammonia is eliminated by the urea 
cycle through renal excretion which is generated by the amino acid 
deamination by transforming it into nontoxic urea. If the urea cycle fails 
to function, ammonia builds up in the blood and thus causes impaired 
mental state, fatigue, cerebral edema, lethargy, and eventually, coma, 
and death [14].
The metabolic condition hyperammonemia is characterized by 
increased ammonia levels, a potent neurotoxin. Hyperammonemia is 
most often represented by neurological signs and symptoms, which 
can be acute or chronic, based on the repressed abnormality [15]. To 
avoid permanent neurological damage, hyperammonemia should be 
detected early and treated promptly. Aside from ammonia, urinary 
organic acids and plasma amino acids are necessary to determine the 
form of UCD [16]. It should be recognized that metabolic disorders 
can be variable and inconsistent. Hence, to validate the diagnosis, 
enzymatic, or molecular analyses are required. In IEMs, early diagnosis 
and administration of adequate therapy are needed to avoid mortality 
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and reduce complications [17]. In the case of suspected IEMs, the 
management should be initiated before the birth [18]. A number of 
IEM-related conditions are detectable by current newborn screening 
(NBS) programs. NBS allows for the detection of an IEM during an 
asymptomatic period and the performance of medical treatments 
that change the disease’s natural history. A few IEM can be treated, 
and as a result, many are incorporated in NBS services in different 
countries [19-21].
OVERVIEW OF UCDS
The urea cycle is the primary mechanism for removing nitrogen waste 
produced by the breakdown of proteins and other molecules containing 
nitrogen by converting the ammonia to urea. The urea cycle comprises 
five catalytic enzymes (CPS1, OTC, ASL, ARG1, and ASS1), two amino 
acid transporters which are Ornithine translocase and Citrin [22,23]. 
Besides this, it consists of N-acetyl glutamate synthetase (NAGS), a co-
factor producing enzyme. UCDs are inborn metabolic errors caused by 
defects in the waste product’s metabolism that is generated during the 
breakdown of protein and other nitrogenous substances [24]. UCDs 
are caused by deficiencies that are inherited in either of the urea cycle 
pathway’s 6 enzymes or 2 transporters (CPS1, OTC, ASS1, ASL, ARG1, 
NAGS, ORNT1, or citrin). The abnormal protein’s role in the pathway, 
as well as the seriousness of the defect, influences the severity of the 
UCD. As a consequence, urea excretion is compromised, resulting in the 
ammonia accumulation and other precursor metabolites [25].
The most common clinical manifestation of UCDs is hyperammonemia. 
Although the severity changes considerably due to the variations that cause 
this disease, it can also be related to defects in at least eight proteins of the 
urea cycle at various stages and may affect them accordingly. In newborns 
with these disorders, ammonia levels frequently reach 1000 mmol/L. 
UCDs are generally characterized by acute and chronic hyperammonemia, 
and medical treatment aims to reduce the concentrations of ammonia by 
limiting protein consumption and using alternative-pathway medications 
to increase nitrogen waste excretion [26,27]. A few studies have shown 
that among various UCDs, just two of the eight diseases, argininosuccinate 
synthetase deficiency (ASSD; or citrullinemia type 1) and lyase deficiency 
(ASLD) may be accurately identified and estimated using tandem mass 
spectroscopy-based NBS.
EPIDEMIOLOGY AND PATHOPHYSIOLOGICAL CLASSIFICATION
In the current developing world, where excellent amenities and 
services are accessible, the average record of the children with UCDs 
still remains unsatisfactory [28]. As hyperammonemia is caused by 
a variety of conditions, acquiring reliable data on its prevalence is 
challenging. The overall prevalence of UCDs is estimated to be 1 in 
every 8000 to 1 in 44,000 live births. In India, all types of UCDs can 
be observed, and the incidence of the disorder is approximately one in 
10,000 births, also indicating a noticeable surge in case identification 
and diagnosis in the past few years.
The clinical classification of UCDs from a pathophysiological 
perspective is mainly based on deficiencies in the enzymes or the 
transporters [29,30].
Carbamoyl phosphate synthetase I deficiency
It is also known as CPS I deficiency (CPSID) which is an autosomal 
recessive UCD that develops due to deficiency of the carbamoyl 
phosphate synthetase I enzyme. CPSID results in an extreme 
nitrogen accumulation in the blood in the form of ammonia causing 
hyperammonemia. The overall incidence of CPSID is predicted to 
occur 1 in 150 to 1 in 200,000 live births. However, since UCDs such as 
CPSID are often not recognized, they are under-diagnosed, making it 
impossible to ascertain the true prevalence of UCDs [31,32].
Ornithine transcarbamylase (OTC) deficiency
The most common UCD in humans is OTC deficiency. The deficient 
enzyme in this condition is OTC, which is the final enzyme in the 
urea cycle proximal portion. It catalyses the conversion of carbamoyl 
phosphate and ornithine into citrulline. OTC deficiency is a hereditary 
condition that induces excess amounts of ammonia to accumulate in 
the blood [33]. The prevalence of OTC deficiency has been estimated 
to be 1 in 14,000 to 1 in 77,000 individuals. The degree of onset of 
OTC deficiency differs from one person to another, often within the 
family [34-38].
Argininosuccinate synthetase deficiency
This deficiency is also called as Citrullinemia. It is a UCD of autosomal 
recessive type. Citrullinemia leads to accumulation of toxic compounds 
and ammonia in the blood [39]. Argininosuccinate synthetase deficiency 
is of two types, that is, Type I citrullinemia (citrullinemia) and Type II 
citrullinemia. The reason for the deficiency is due to mutations in genes 
which differ for both the types and clinical manifestations are also 
different [40-42]. The most common type of Citrullinemia is Type I 
citrullinemia exhibiting overall incidence more than 1 in 57,000 of 
global population. Type II citrullinemia shows prevalence of one in 
100,000 to 230,000 people and is found majorly in the population of 
Japan.
Argininosuccinic aciduria (ASA)
ASA is a genetic disorder that occurs due to the partial or complete 
deficiency of argininosuccinate lyase (ASL) enzyme and it is the second 
most common type of UCD. This deficiency leads to the argininosuccinic 
acid accumulation in the urine and blood. ASA can be observed probably 
1 in 70,000 to 1 in 218,000 live births, and this disorder accounts for 
16% of overall UCDs. Mostly, this disorder can be recognized through 
NBS after the birth of the child [43-45].
Arginase deficiency (Argininemia)
Arginase deficiency results in the gradual accumulation of ammonia 
and an amino acid called arginine in the blood, and it is a very 
rare heritable genetic disorder. The clinical manifestations include 
spasticity in the muscles, particularly in the legs, and the disorder can 
be identified by the age of three. The symptoms may be of low severity 
in some individuals and might not appear till a certain age. The overall 
prevalence of the disorder is one in every 300,000 to 1,000,000 [46-49].
NAGS deficiency
NAGS deficiency occurs due to defects in the enzyme NAGS which is the 
rarest type of UCD and was first identified in 1981. The clinical features 
of this deficiency are not evident usually till later stages of life in a 
few affected individuals, and the severity of the disorder is based on 
the partial or complete lack of the NAGS enzyme. The incidence of this 
disorder is reported to be less than one in 2,000,000 individuals [50-52].
Ornithine translocase deficiency
It is a genetically heritable disorder that leads to accumulation of 
ammonia and other toxic compounds in the blood of affected individuals. 
Ornithine translocase deficiency rarely occurs and is estimated to have 
an overall prevalence of about 100 affected people as mentioned in the 
scientific literature [53,54].
INHERITANCE AND GENETIC CAUSE
The inheritance of the UCDs is the following types [55-57].
X-linked
OTC deficiency is the most common type of UCD that is generally passed 
on from mother to child through the X-chromosome who is not affected 
mostly. When this gene is inherited by a male individual, will more likely 
exhibit symptoms, whereas in women the symptoms may be observed 
or do not exist. Hence, they are called carriers of the disorder.
Autosomal recessive
Apart from OTC, in all the other UCDs, the defective gene is carried by 
both the parents and passes on a copy of this gene. When an individual 
inherits two copies of the same gene, it leads to UCD and may exhibit 
related symptoms.
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Random mutation
This is also termed as “de novo,” a type of mutation which results in 
a defective gene development at the cell forming stage, consequently 
leading to UCD.
Different forms of UCDs are caused by various genes. There are eight 
distinct forms of UCDs, which are also referred to as “subtypes.” The 
UCD genes encode the urea cycle enzymes as well as those needed 
for their effective functioning, and defects in these genes results in 
disorders [58]. The genes that are involved in UCDs are OTC encoding 
OTC, ASL encoding ASL, NAGS encoding NAGS, ASS1 encoding 
argininosuccinate synthetase, CPS1 encoding carbamoyl phosphate 
synthetase I, ARG1 encoding arginase 1, SLC25A13 encoding citrin, and 
SLC25A15 encoding the mitochondrial ornithine translocator.
CLINICAL PRESENTATION
The clinical manifestations of UCDs are induced by defects in the 
enzymes or products, accumulation of toxic compounds or sometimes 
both. The onset of the clinical symptoms will range from the newborn 
phase to adulthood, depending on the deficient enzyme’s residual 
function. In UCDs, the clinical symptoms are generally nonspecific and 
are psychological, gastrointestinal, or neurological in nature. UCDs can 
appear as acute or chronic symptoms, and clinical signs and symptoms 
can occur at any age of 12–16 [59,60]. These are often caused by excess 
load of protein, catabolic activities, or due to some medications. In 
certain instances, it is impossible to identify a precipitating cause [61]. 
Most UCDs are distinguished by hyperammonemia, a nonspecific 
indicator of insufficient detoxification of nitrogen [62]. UCD is 
distinguished by the fact that ammonia toxicity is at a high range based 
on whether the blockage is in the initial or next level.
Hyperammonemia causes cerebral edema, hypothermia, neurologic 
posturing, lethargy, hyperventilation or hypoventilation, anorexia, 
fatigue, and coma which are the symptoms of this condition [63-65]. 
Hyperammonemic crisis may occur due to extended periods of fasting 
and mild illness with fever or low oral intake because of high proteolysis 
and catabolism. Similarly, consumption of excess protein leads to 
elevated ammonia production and, as a result, causes encephalopathy. 
In a few cases, impairment in the liver or administration of valproic acid 
also causes hyperammonemia. Hence, the patients should be tested for 
any of these disorders. Based on the proximity of defects in the enzyme, 
the severity of hyperammonemia can be estimated. Therefore, the UCD 
subtypes incidence is NAGS deficiency, carbamoyl phosphate synthetase 
I deficiency, OTC deficiency, argininosuccinate synthetase deficiency, 
ASA, and arginase deficiency in the descending order [66,67].
DIAGNOSTIC METHODS
The diagnosis of UCDs can be made by urinary orotic acid and plasma 
amino acid analysis [68]. In general, the metabolic abnormalities are 
considered to be inconsistent and vary accordingly. There are various 
diagnostic methods for the detection of UCDs and their subtypes.
NBS and Differential diagnosis
At present, NBS employs tandem mass spectrometry to detect the 
UCDs [69-71]. Moreover, the specificity and reliability for the UCDs 
using this screening technique varies [72]. Hyperammonemia can 
also be caused by a few other disorders that affect the liver and thus 
resemble the characteristics of UCD [73]. These include the use of 
some drugs such as valproic acid, cyclophosphamide, diseases of the 
biliary tract, and liver as well as other genetically related disorders. 
Various genetic disorders such as propionic acidemia, and isolated 
methylmalonic acidemia are taken into consideration for differential 
diagnosis of UCDs [74].
Prenatal testing
In many countries, prenatal testing is available that enables termination 
of pregnancy in case of abnormality in the fetus [75]. Prenatal analysis 
aid in perinatal management and can also indicate the presence of 
UCDs at the milder range. A counseling session by metabolic specialists 
and clinical geneticists is essential for the prenatal testing [76,77]. 
Mutation analysis is the tool of choice for reliable detection of UCDs, 
genetic counseling, and, in some cases, predicting prognosis. One of 
the examples for this testing is mutation analysis from CVS or AFC for 
CPS1D disorder using the DNA.
Molecular genetic testing
The diagnostic method which is primarily used for the accurate 
detection and confirmation of all the UCDs is molecular genetic testing. 
Molecular genetic testing is a preferential prenatal method for all the 
eight UCDs. The analysis of enzyme activity is supplanted by this method 
as a reliable diagnostic method. It includes consideration of the single 
and multi-gene testing; exome sequencing; and genome sequencing.
Enzyme activity assay
In case of uninformative molecular genetic testing, enzyme activity 
assay is a reliable method to detect UCDs. Enzyme activity can be 
helpful if the estimation based on DNA is not appropriate, and it can 
detect most of the disorders. If the molecular testing fails to detect 
particular UCD, enzyme activity assays involve the use of erythrocytes, 
intestinal mucosa, fibroblasts, and liver tissue for the detection [78].
PROGNOSIS
The prognosis for UCDs is mainly based on the primary condition that 
causes the increase in levels of ammonia. Patients of UCDs with early 
and late-onset of hyperammonemia were estimated to be 35% and 
87%, respectively, in an 11-year survival rate. In individuals affected 
with serious hepatic encephalopathy, the probability of survival is 
recorded to be around 42% and 23% in individuals with 1 and 3 years 
of age [79].
MANAGEMENT OF UCDS
At present, there is no available treatment for UCDs. The type of 
urea cycle disease depends on the early or late diagnosis, acute 
manifestations, and implementation of the plan of diet and treatment. 
For the child to have positive outcomes, early intervention and care are 
required. Babies that are diagnosed within the 1st week of birth and 
immediately placed on a diet may improve the condition. Normal brain 
activity will be achieved by adhering to the diet. Thus, the nutrition 
therapy must be provided based on the severity of the disorder, despite 
the availability of various medications for the elimination of nitrogen. 
With the use of appropriate treatments methods, the survival rate can 
be prolonged in affected individuals [9,80-83].
Management of acute manifestations
In the earlier times, with respect to UCDs, the morbidity and mortality 
were in the highest range and severe neurological consequences 
have been experienced by the affected individuals. The prognosis 
and predicted neurodevelopmental outcome should be noticed 
when treating acute hyperammonemia since they would affect the 
clinical decision [84]. The management of acute hyperammonemic 
manifestations includes restriction of protein in diet, regulation of high 
concentration of plasma ammonia to normal levels [85], management of 
catabolic state, treating seizures, and preventing overload of fluids must 
be considered for reducing the risk of neurological damage. Alternative 
pathway therapy can be suggested for the elimination of excess nitrogen. 
This therapy utilizes the administration of sodium phenylbutyrate or 
sodium phenylacetate/benzoate for the nitrogen elimination in the 
form of hippuric acid and phenylacetylglutamine [86,87].
Long-term management
The main idea for long-term management of the UCDs is to attain 
normal growth and development and to prevent hyperammonemia 
condition. This type of management is based on supplementation of 
essential amino acids, vitamins and minerals, maintenance of low 
protein diet, and replacement of arginine and citrulline [88] based on 
the UCD subtype condition of the affected individual and also involves 
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pharmacological assistance for elimination of excess nitrogen like 
sodium benzoate [89].
Recently, commonly available Glycerol phenylbutyrate is used as a 
pharmacological treatment that ensures improved patient condition. 
In severe cases of the UCD affected children, liver transplantation 
is recommended [90,91]. A treatment plan including emergency 
instructions and information about contacting the local hospital or for 
metabolic assistance must be provided in advance to the caretakers or 
parents.
Liver transplantation
The sole treatment or cure for UCDs is liver transplantation, which allows 
for a transition to a normal diet and the cessation of pharmacological 
treatment. Transplantation of hepatocyte is being suggested as a 
bridging therapeutic procedure in affected patients with UCD [92]. At 
present, trials are being conducted to assess the procedure’s safety 
and effectiveness. Management of the disorder which includes liver 
transplantation, for all UCDs except NAGSD and the HHH syndrome, 
is treatable in terms of enzyme deficiencies and helps with the low-
protein diet and alternative pathway therapy discontinuation, although 
it does not reverse the existing neurological impact [93].
Transplanted patients need immunotherapy as well as long-term 
monitoring. Thus, in terms of quality of life, liver transplantation is 
a safer approach to conventional care for seriously affected UCD 
patients when compared with the medical treatment [94,95]. As 
the pre-existing neurological injury exists, it is critical to avoid 
hyperammonemia and endogenous catabolism before and throughout 
liver transplantation.
Gene replacement therapy
Recently, gene therapy has been known to be effective for treating 
various metabolic disorders including UCDs. Gene therapy can be used 
for delivering the therapeutic gene specifically to the liver, which can 
eventually result in normal ammonia levels. Based on information 
from the previous research, adeno-associated viral (AVV) vectors are 
considered as primary agents of the gene therapy for UCDs among 
various other multiple vector systems due to their efficiency. Liver-
directed gene replacement therapy using AVV vectors for ARG1 
deficiency, ASL deficiency, ASS1 deficiency, and OTC deficiency has been 
reported in a few animal models [96-99].
Patient monitoring
UCD patients acquiring medical treatment need lifetime supervision, 
which includes anthropometric results, metabolic testing, food 
and medication reviews, history of coexisting conditions, and the 
use of the emergency instructions. Person visit periods should be 
determined based on age, development, severity, physiological health, 
and adherence to diet and drug therapy. Younger and more seriously 
affected patients may need testing every 3 months, whereas older or 
less severely affected patients will only need yearly reviews. Assessment 
on the diet should be performed on a regular basis. The diet must be 
planned according to age and development. As low protein diets can 
raise the risk of osteoporosis, bone density screening may be necessary 
from time to time [100].
DETERRENCE AND PATIENT EDUCATION
The information regarding the clinical manifestations of UCDs must 
be familiarized to the affected patients. Knowledge and education 
concerning medical compliance are crucial. Each individual patient 
must be provided with a specific diet plan and information related 
to particular dietary supplements also to be given. The growth and 
development must be constantly monitored in children affected with 
UCD, and parents must be advised on the condition accordingly. As many 
of these conditions are treatable, patient education and knowledge 
about IEMs leads to early diagnosis and effective treatment that can be 
lifesaving [101-103].
CONCLUSION
Inborn metabolic errors belong to a heterogenous class of disorders 
that can occur due to inheritance or as a consequence of mutations of 
spontaneous type. UCD are a common type of IEMs that are caused by 
the defects in enzymes of the urea cycle pathway resulting in excessive 
accumulation of certain metabolites and mainly ammonia. In general, 
UCDs are genetic disorders, and all of these except OTC deficiency 
are autosomal recessive disorders. Whereas the OTC deficiency is an 
X-linked inherited disorder. UCDs exhibit common clinical signs of 
hyperammonemia which causes disruption of neurotransmitters, 
functioning of mitochondria in the brain, ion gradients and metabolites 
transportation, especially in newborns after a few periods of feeding. 
In most of the cases, prevention of severe neurological damage and 
death in UCDs mainly depend on early diagnosis and consideration of 
effective treatment methods. IEMs can be diagnosed accurately using 
NBS, which can detect these disorders at an asymptomatic stage and 
perform medical intercessions that positively change the disease’s 
natural history. Even in the case of negative NBS results, the clinicians 
must still recognize the probability of the disorder. Early diagnosis and 
appropriate treatment ensure attaining the advantages of these recent 
developments in the affected individuals. In particular, the number of 
treatable IEMs is increasing over time, and care for the disorders that 
are not treatable is improving.
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